Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cetraxate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 known ✓ | P05106 | 1/20 | 0.44 |
| ▸ | ITGA2B known ✓ | P08514 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.97 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | ELANE | P08246 | 2/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 11/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | PLG | P00747 | 1/20 | 0.41 |
| ▸ | PLAT | P00750 | 1/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cetraxate SCHEMBL144285 | 1.00 | F2 (0.97) | F2HTTKMT2ASMN1; SMN2TDP1 | |
| Cetraxate SCHEMBL7616457 | 0.99 | F2 (1.00) | F2HTTKMT2ASMN1; SMN2TDP1 | |
| Cetraxate SCHEMBL20774010 | 0.99 | F2 (1.00) | F2HTTKMT2ASMN1; SMN2TDP1 | |
| Cetraxate SCHEMBL19437 | 0.99 | F2 (1.00) | F2HTTKMT2ASMN1; SMN2TDP1 | |
| Cetraxate SCHEMBL476429 | 0.99 | F2 (1.00) | F2HTTKMT2ASMN1; SMN2TDP1 | |
| Cetraxate SCHEMBL4639111 | 0.97 | F2 (0.97) | F2HTTKMT2ASMN1; SMN2TDP1 | |
| Cetraxate SCHEMBL11215310 | 0.97 | F2 (0.97) | F2HTTKMT2ASMN1; SMN2TDP1 | |
| Cetraxate SCHEMBL10789557 | 0.97 | F2 (0.97) | F2HTTKMT2ASMN1; SMN2TDP1 | |
| Cetraxate SCHEMBL11215307 | 0.97 | F2 (0.97) | F2HTTKMT2ASMN1; SMN2TDP1 | |
| Cetraxate SCHEMBL1649792 | 0.96 | F2 (0.95) | F2HTTKMT2ASMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 746 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20110159049-A1 | PHARMACEUTICAL COMPOSITION | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-06-30 | — | — | US | claimed |
| CN-1343128-B | Medicinal compositions | DAICHI PHARMACEUTICAL CO LTD | 2010-04-21 | — | — | CN | claimed |
| CN-101234200-A | Composition for improving and treating human body digestive system a plurality of malaise symptoms | BINGHUA GUO (CN) | 2008-08-06 | — | — | CN | claimed |
| US-20070196504-A1 | PHARMACEUTICAL COMPOSITION | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-08-23 | — | — | US | claimed |
| US-20070148235-A1 | PHARMACEUTICAL COMPOSITION | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-06-28 | — | — | US | claimed |
| CN-1247188-C | Pharmaceutical composition | DAIICHI SEIYAKU CO (JP) | 2006-03-29 | — | — | CN | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-6287596-B1 | DRUG DELIVERY | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-09-11 | — | — | US | claimed |
| CN-1280506-A | Oral Preparation | DAIICHI SEIYAKU CO (JP) | 2001-01-17 | — | — | CN | claimed |
| EP-1020193-A1 | ORAL PREPARATION | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2000-07-19 | — | — | EP | claimed |
| CN-1225017-A | Quickly disintegrable compression-molded materials and process for producing the same | DAIICHI SEIYAKU CO (JP) | 1999-08-04 | — | — | CN | claimed |
| EP-0922464-A1 | QUICKLY DISINTEGRABLE COMPRESSION-MOLDED MATERIALS AND PROCESS FOR PRODUCING THE SAME | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1999-06-16 | — | — | EP | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| US-5700410-A | Method of manufacturing wax matrices | NIPPON SHINYAKU CO., LTD. (JP) | 1997-12-23 | — | — | US | claimed |
| EP-0580860-B1 | METHOD OF MANUFACTURING SOLID DISPERSION | NIPPON SHINYAKU CO LTD (JP) | 1997-10-22 | — | — | EP | claimed |
| US-5288503-A | WATER-PERMEABLE DIFFUSION BARRIER OF POLYVINYL ALCOHOL | SRCHEM INCORPORATED (US) | 1994-02-22 | — | — | US | claimed |
| US-5260066-A | Cryogel bandage containing therapeutic agent | SRCHEM INCORPORATED (US) | 1993-11-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070148235-A1 | PHARMACEUTICAL COMPOSITION | TAS2R5, TAS2R60, TAS2R16 | ITGB3 2343/4885ITGA2B 2401/4885F2 2243/4885 |
| US-20110159049-A1 | PHARMACEUTICAL COMPOSITION | TAS2R5, TAS2R60, TAS2R16 | ITGB3 2343/4885ITGA2B 2401/4885F2 2243/4885 |
| US-20070196504-A1 | PHARMACEUTICAL COMPOSITION | CMA1, HRH2, ACLY | ITGB3 487/4885ITGA2B 407/4885F2 1196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.